BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

XTend Medical (XMDC.PK) Confirms Acquisition of the BioHarp Assets


10/4/2010 9:44:25 AM

SUN VALLEY, CA--(Marketwire - October 04, 2010) -

XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, has successfully acquired the BioHarp Assets from Mr. Sang M. Lee and U&I Bio-Tech, Inc., as provided in the Asset Purchase Agreement that the parties signed on December 9, 2009. XTend's representatives and Mr. Lee completed the acquisition last Thursday, September 30, 2010, through a mediation proceeding in the Delaware Chancery Court.

The company released the following statement, "We are delighted that the mediation last Thursday was successful. Through the assistance of our litigation counsel, Mr. John Holcomb of Knobbe, Martens, Olson & Bear, LLP and Mr. David Teklits of Morris, Nichols, Arsht & Tunnell LLP, along with the wisdom and guidance of the mediator, Master Sam Glasscock III of the Delaware Chancery Court, XTend has finally secured the BioHarp assets, including the BioHarp patents and other intellectual property. XTend now can move forward with its plans to manufacture and commercialize the BioHarp technology so that the company can capitalize on the healthcare, veterinary, and horticulture industries. The company is eager to make sales in Korea, Japan, China, and the U.S. as quickly as possible. Additionally, XTend will work to complete audited financials expeditiously in order to become a fully reporting company. The company anticipates being listed on a higher exchange within the first quarter of 2011. Finally, the company would like to thank its loyal shareholders for their patience while this BioHarp acquisition process has progressed. The company is confident in its future as a leader in the medical technology sector."

About XTend Medical

XTend Medical Corporation is a company that specializes in the sale, manufacturing, and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. The company is dedicated to insuring that the products and services that it offers to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. XTend's recent acquisition of the BioHarp medical device will assist the company in becoming known as a leader in the healthcare sector globally. For further information, please contact the company at info@bioharpunius.com or visit its website at www.bioharpunius.com.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.


CONTACT
XTend Medical Corporation
info@bioharpunius.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->